HemoDefend™ – Ensuring the quality and safety of the blood supply by reducing antibodies, cytokines, free hemoglobin, bioactive lipids, and other contaminants that can cause transfusion reactions and adverse events.. Currently being developed for pRBCs and universal plasma

CytoSorb-XL – Represents the next generation of CytoSorb, that includes the ability to remove lipopolysaccharide (LPS) endotoxin

Potassium Binder – Designed to reduce potassium in blood to treat severe hyperkalemia

DrugSorb – Targeting the improvement in outcomes in drug overdose by actively removing drugs and medications from the blood

Others

CytoSorbents has established relationships with industry-leading partners including Fresenius, Terumo and Biocon.

CytoSorbents seeks partnerships and collaborations with industry leaders in a variety of different verticals, including blood purification, critical care and acute care medicine, cardiac surgery, immunotherapy, and others. None of these products have yet been approved for sale in the United States.